-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate cost of goods produced and sold and services rendered during the reporting period.
-
Summary
-
Endonovo Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from 2018 to 2022.
- Endonovo Therapeutics, Inc. Cost of Revenue for the quarter ending September 30, 2023 was $827.000, a 79.5% decline year-over-year.
- Endonovo Therapeutics, Inc. annual Cost of Revenue for 2022 was $9.99K, a 33.3% decline from 2021.
- Endonovo Therapeutics, Inc. annual Cost of Revenue for 2021 was $15K, a 77.1% decline from 2020.
- Endonovo Therapeutics, Inc. annual Cost of Revenue for 2020 was $65.4K, a 30% decline from 2019.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Growth (%)